

Dr Lalchandani Labs Ltd.

lalchandaniopathlab.com

January 31, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 541299

Dear Sir/Madam,

Subject: Newspaper publication Intimation under Regulation 84(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") and Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In Compliance with Regulations mentioned in the captioned subject, kindly find enclosed herewith copies of newspaper advertisements published by the Company today, i.e. 31st January, 2026 in Financial Express (English- All Edition), Jansatta (Hindi- All editions), inter alia, intimating the details of the date of completion of dispatch of the letter of offer and application form, details where shareholders or persons entitled to receive rights entitlement may obtain duplicate copies of applications forms and details in relation to applications on plain paper by shareholders.

Kindly take the same in your records.

FOR Dr Lalchandani Labs Limited



Arjan Lal Chandani
Managing Director
DIN: 07014579



"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

FORM G

INVITATION FOR EXPRESSION OF INTEREST FOR BLU-SMART FLEET PRIVATE LIMITED, OPERATING IN the businesses of hiring of all types of Cars

(Under Sub-Regulation (1) of regulation 36A of the Insolvency & Bankruptcy Board of India (Insolvency Resolution Process for Corporate Persons) Regulations, 2016)

SL	RELEVANT PARTICULARS
1	Name of the corporate debtor along with PAN/ CIN/ LLP No.
2	Address of the registered office
3	URL of website.
4	Details of place where majority of fixed assets are located
5	Installed capacity of main products/ services
6	Quantity and value of main products/ services sold in last financial year
7	Number of employees/ workmen
8	Further details including last available financial statements (with schedules) of two years, lists of creditors are available at URL:
9	Eligibility for resolution applicants under section 25(2)(h) of the Code is available at URL:
10	Last date for receipt of expression of interest
11	Date of issue of provisional list of prospective resolution applicants
12	Last date for submission of objections to provisional list
13	Date of issue of Final list of prospective resolution applicants
14	Date of issue of Information Memorandum, Evaluation Matrix and Request for Resolution Plan to prospective resolution applicants
15	Last date for submission of Resolution Plans
16	Process email id to Submit Expression of Interest
17	Details of the corporate debtor's registration status as MSME

Date: 31.01.2026
Place: New Delhi

PAWAN KUMAR GOYAL
Interim Resolution Professional of M/s Blu-Smart Fleet Private Limited,
IP Reg Number: IBI/II/PA-001/IP-P00875/2017-18/11473
(Authorization for Assignment valid till: 31/12/2026)
Office: 304, D R Chamber, 12/56,
D B Gupta Road, Karol Bagh, New Delhi

SECOND QUARTERLY NOTICE IN RESPECT OF EXIT OFFER TO THE EQUITY SHAREHOLDERS OF EASTERN GENERAL INDUSTRIES LIMITED

CIN: U01131WB1952PLC020342,
Registered Office: 90/31, Diamond Harbour Road, Kolkata - 700 038,
Tel. No.: 033- 2398-3475 / 3289, Email: official@rawjute.in, Website: www.rawjute.in

This second quarterly notice in respect of Exit Offer ("Exit Offer Notice 2") is being issued in accordance with Regulation 27 of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 as amended (the "Delisting Regulations") and in compliance with SEBI Exemption Letter SEBI/HO/CFD/CFD-RAC-DCR1/PI/OW/2023/44667/1 dated November 06, 2023, by Mr. Harsh Vardhan Kejriwal forming part of the Promoters/ Promoter Group (hereinafter referred to as the "Promoter Acquirer") of Eastern General Industries Limited (hereinafter referred to as the "Company"/ "EGIL"), to provide the Remaining Public Shareholders ("Residual/ Remaining Public Shareholders") of EGIL an exit opportunity. The Acquirer intends to acquire 4500 (Four Thousand and Five Hundred) equity shares representing 2.25% of fully paid-up equity share capital of the Company held by the Residual Public Shareholders. This Exit Offer Notice 2 is in continuation of and should be read in conjunction with the Initial Public Announcement dated December 05, 2023 ("Initial Public Announcement"/ "IPA"), the Offer Letter ("Offer Letter") dated December 17, 2024, the Exit Offer Public Announcement ("Exit Offer PA") dated July 16, 2025 published on July 17, 2025, Exit Offer Letter dated July 16, 2025 and Exit Offer Notice 1 dated October 23, 2025 published on October 24, 2025.

The equity shares of the Company have been delisted from The Calcutta Stock Exchange Limited ("CSE") i.e., the only Stock Exchange where the equity shares of the Company were listed, with effect from July 08, 2025 ("Date of Delisting").

1. OUTSTANDING EQUITY SHARES AFTER DELISTING

- 1.1 As the equity shares of the Company have already been delisted, the Acquirer has provided an Exit Offer in accordance with Regulation 26 of the Delisting Regulations and in compliance with SEBI Exemption letter SEBI/HO/CFD/CFD-RAC-DCR1/PI/OW/2023/44667/1 dated November 06, 2023, as announced earlier in the Exit Offer PA. The remaining Public Shareholders of the Company who did not or were not able to tender their equity shares or who unsuccessfully tendered their equity shares will be able to offer their equity shares to the Acquirer at the price of Rs. 200.50 (Rupees Two Hundred and Fifty Paise Only) ("Exit Price") for a period of two year starting from the Date of Delisting i.e., from July 08, 2025 to July 07, 2027 ("Exit Period").
- 1.2 The Exit Offer Letter ("Exit Offer Letter") in this regard has been dispatched to the remaining Public Shareholders whose names appeared in the register of members of the Company as on July 11, 2025. In the event of any shareholder not receiving or misplacing their Exit Offer Letter, they may obtain a copy by writing to the Company, clearly marking the envelope "EGIL- EXIT OFFER" at 90/31, Diamond Harbour Road, Kolkata - 700 038. Alternatively, the soft copy of the exit offer letter may be downloaded from the website of the Company at www.rawjute.in.

1.3 Shareholders holding in Dematerialised Form:

The beneficial owner and public shareholders will be required to send their Tender Form and other relevant documents to the Promoter Acquirer at 90/31, Diamond Harbour Road, Kolkata - 700038, either by registered post / courier or by hand delivery, at address mentioned above, along with a photocopy of the delivery instructions in "Off-market" mode or counterfoil of the delivery instructions in "On-market" mode, duly acknowledged by the depository participant ("DP"), in favour of "Eastern General Industries Ltd. Delisting Escrow Demat Account" filled in as per the instructions given below:

Name of the Account in which Equity Shares will be Transferred	Eastern General Industries Ltd. Delisting Escrow Demat Account
Name of Depository	National Securities Depository Limited
Name of Depository Participant	Anand Rathi Share and Stock Brokers Limited
Depository Participant's ID No.	IN301803
Client ID No.	10047126
ISIN No.	INE0GU001016

2. PAYMENT OF CONSIDERATION TO RESIDUAL SHAREHOLDERS:

Subject to any regulatory approvals as may be required, the Acquirer intends to make payments on monthly basis, within 15 days of the end of the relevant calendar month ("Monthly Payment Cycle"). The first Monthly Payment Cycle commenced within 15 days from December 01, 2025 for Equity Shares tendered upto November 30, 2025. Payments will be made only to those shareholders who have validly tendered their equity shares by following the instructions laid out in the Exit Offer Letter and the application form enclosed therewith ("Exit Application Form"). Please note that the Acquirer reserves the right to make payments earlier.

Capitalized terms used but not defined in this Exit Offer Notice 2 shall have the same meaning assigned to them as in the IPA, Offer Letter, Exit Offer PA, Exit Offer Letter and Exit Offer Notice 1. In case the Public Shareholders have any query, they may contact the Compliance Officer of the Company i.e., Mr. Ravi Singh at ravisingh@rawjute.in.

Sd/-
Harsh Vardhan Kejriwal
(On behalf of self and other constituents of the Promoter / Promoter Group)

Place: Kolkata
Date: 30.01.2026



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office: Block E, Sector-18, Rohini, New Delhi-110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon-122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468

Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Extract of Consolidated Unaudited Financial Results for the quarter & nine months ended 31 December, 2025

(Rs. in million except as stated)				
S. No.	Particulars	3 months ended 31 December, 2025	Nine months ended 31 December, 2025	Corresponding 3 months ended 31 December, 2024
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income from Operations	6,842	21,375	6,218
2	Net Profit for the period before Tax and Exceptional Items*	1,544	5,391	1,383
3	Net Profit for the period before Tax and after Exceptional Items*	1,243	5,090	1,383
4	Net Profit for the period after Tax and after Exceptional Items*	914	3,776	981
5	Total Comprehensive Income for the period after tax*	917	3,785	980
6	Paid up Equity Share Capital (face value of INR 10/- per share)	1,676	1,676	836
7	Earnings Per Share (of INR 10/- each) (not annualised)			
	(a) Basic (In INR)	5.42	22.38	5.80
	(b) Diluted (In INR)	5.41	22.35	5.79

*Before non-controlling Interest

Notes:
i. Key numbers of the Standalone Results are as under:

(Rs. in million except as stated)				
Particulars	3 months ended 31 December, 2025	Nine months ended 31 December, 2025	Corresponding 3 months ended 31 December, 2024	
	(Unaudited)	(Unaudited)	(Unaudited)	
Total Income from Operations	6,587	20,481	6,005	
Profit for the period before Tax and Exceptional Items	1,532	5,204	1,436	
Profit for the period before Tax and after Exceptional Items	1,231	4,903	1,436	
Profit for the period after Tax and after Exceptional Items	921	3,671	1,054	
Total comprehensive income	924	3,678	1,053	

- ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2026.
- iii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - "Operating Segments", notified under the Companies (Indian Accounting Standard) Rules, 2015.
- iv. The consolidated other equity(excluding revaluation reserve) as on 31 March 2025 is 20.891 Million.
- v. The above is an extract of the detailed format of Quarterly and nine months financial results as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the quarter and nine months ended 31 December, 2025 is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of Dr. Lal PathLabs Limited

Sd/-
(Hony) Brig. Dr. Arvind Lal
Executive Chairman

For More Information Please Scan:



Place: Gurugram
Date: 30 January, 2026

This advertisement is for information purpose only and does not constitute an offer or an invitation or a recommendation to purchase, to hold or sell the securities. This is not an announcement for the offer document.



DR LALCHANDANI LABS LIMITED

Dr Lalchandani Labs Limited (our "Company" or the "Issuer") was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017. For details of changes in the name and registered office of our Company, see "General Information" on page 01 of this Letter of Offer.

Registered Office: M-20 Basement, Greater Kailash-1, South Delhi, New Delhi, India, 110048 | Telephone: + (91) 9873972036 | Contact Person: Saniya Hussain, Company Secretary and Compliance Officer Email: info@lalchandanipathlab.com, Website: https://lalchandanipathlab.com CIN: LB5320DL2017PLC321605

PROMOTER OF OUR COMPANY: MR. ARJAN LAL CHANDANI, MR. MOHIT LAL CHANDANI & MS. ANCHAL GUPTA

FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF THE DR LALCHANDANI LABS LIMITED (THE "COMPANY" OR "THE ISSUER") ONLY

ISSUE OF UP TO 43,32,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH, AT PAR, AT A PRICE OF ₹10 PER RIGHTS EQUITY SHARE ("ISSUE PRICE") AGGREGATING UP TO ₹433.20 LAKHS ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 01 (ONE) RIGHTS EQUITY SHARE FOR EVERY 01 (ONE) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON TUESDAY, JANUARY 27, 2026 ("RECORD DATE") (THE "ISSUE"). FOR FURTHER DETAILS, PLEASE SEE "TERMS OF THE ISSUE" BEGINNING ON PAGE 62 OF THE LETTER OF OFFER.

*Assuming full subscription. Subject to finalisation of the Basis of Allotment

NOTICE TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY

ISSUE OPENS ON
Wednesday, February 04, 2026

LAST DATE FOR ON MARKET RENUNCIATION*
Tuesday, February 17, 2026

ISSUE CLOSING ON#
Friday, February 20, 2026

*Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that the Rights Entitlements are credited to the demat account of the Renouncers on or prior to the Issue Closing Date.

Our Board or a duly authorised committee thereof will have the right to extend the Issue period as it may determine from time to time, but not exceeding 30 (thirty) days from the Issue Opening Date (inclusive of the Issue Opening Date). Further, no withdrawal of Application shall be permitted by any Applicant after the Issue Closing Date.

ASBA*

Simple, Safe, Smart way of Application. Make use of it.!!!

* Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, investors can avail the same. For details, check the section on ASBA below.

FACILITIES OF APPLICATION IN THE ISSUE

In accordance with Regulation 76 of the SEBI ICDR Regulations, the SEBI Master Circular and the ASBA Circulars, all Shareholders desiring to make an Application in this Issue are mandatorily required to use the ASBA process. Shareholders should carefully read the provisions applicable to such Applications before making their Application through ASBA.

For details, see "Making of an Application through the ASBA process" on Page 68 of the Letter of Offer.

Please note that subject to SCSBs, complying with the requirement of SEBI Circular bearing reference number CIR/CFD/DIL/1/2013 dated January 02, 2013, it is clarified that for making Applications by SCSBs on their own account using ASBA facility, each such SCSB should have a separate account in its own name with any other SEBI-registered SCSB(s). Such account shall be used solely for the purpose of making an Application in this issue and credit demeritised funds should be available in such account for such an application.

CREDIT OF RIGHT ENTITLEMENTS IN DEMAT ACCOUNTS OF ELIGIBLE EQUITY SHAREHOLDERS: In accordance with Regulation 77A of the SEBI ICDR Regulations, read with SEBI ICDR Master Circular, the credit of Right Entitlements and Allotment of Right Equity Shares shall be made in the dematerialised form only.

PLEASE NOTE THAT CREDIT OF RIGHT ENTITLEMENTS IN THE DEMAT ACCOUNT DOES NOT, PER SE, ENTITLE THE INVESTORS TO THE RIGHT EQUITY SHARES AND THE INVESTORS HAVE TO SUBMIT AN APPLICATION FOR THE RIGHT EQUITY SHARES ON OR BEFORE THE ISSUE CLOSING DATE BY MAKING FULL PAYMENT TOWARDS SHARES APPLIED. FOR FURTHER DETAILS, PLEASE SEE THE "TERMS OF THE ISSUE-PROCESS OF MAKING AN APPLICATION IN THE ISSUE" ON PAGE 68 OF THE LETTER OF OFFER.

PLEASE NOTE THAT THE RIGHT ENTITLEMENTS, IF NO APPLICATION IS MADE BY THE ELIGIBLE EQUITY SHAREHOLDERS OF RIGHTS ENTITLEMENTS ON OR BEFORE THE ISSUE CLOSING DATE, SUCH RIGHTS ENTITLEMENTS SHALL LAPSE AND SHALL BE EXTINGUISHED AFTER THE ISSUE CLOSING DATE

Please note that our Company has opened a separate demat suspense Escrow Account (namely, "DR LALCHANDANI LABS LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT") (Demat Suspense Account) and has credited the Right Entitlements on the basis of the Equity Shares (a) held by Eligible Equity Shareholders which are held in physical form as on Record Date, or (b) which are held in the Account of the Investor Education and Protection Fund (IEPF) authority, or (c) of the Eligible Equity Shareholders whose demat accounts are frozen or where the Equity Shares are lying in the unclaimed/suspense escrow account/ demat suspense account/ demat suspense account (including those pursuant to Regulation 39 of the SEBI (LODR) Regulations or details of which are unavailable with our Company or with the Registrar on the Record Date or where the Equity Shares have been kept in abeyance or where instructions have been issued for stopping issue or transfer or where the letter of confirmation lying in the escrow account, or (d) where credit of the Right Entitlements have returned/reversed/failed for any reasons; (e) where ownership is currently under dispute, including any court or regulatory proceedings or where any legal notices have been issued, if any or (f) such other cases where our Company is unable to credit Right Entitlements for any other reasons. Please note that our Company has credited the Right Entitlements to the Demat Suspense Account on the basis of information available with our Company and to serve the interest of the Eligible Equity Shareholders to provide them a reasonable opportunity to participate in the issue. The credit of the Right Entitlements to the Demat Suspense Account by our Company does not create any right in favour of the relevant Eligible Equity Shareholder for transfer of the Right Entitlement to their demat account or to receive any Equity Shares in the Issue.

With respect to the Right Entitlements credited to the Demat Suspense Account, the Eligible Equity Shareholders are requested to provide relevant details/documents as acceptable to our Company or the Registrar (such as applicable regulatory approvals, self-attested PAN and client master sheet of demat account, details/records confirming the legal and beneficial ownership of their respective Equity Shares, etc.) no later than two clear Working Days prior to the Issue Closing Date i.e., by Wednesday, February 18, 2026, to enable credit of their Right Entitlements by way of transfer from the Demat Suspense Account to their Demat Account at least one day before the Issue Closing Date, to enable such Eligible Equity Shareholders to make an application in this issue, and the communication shall serve as an Intimation to such Eligible Equity Shareholders in this regard. Such Eligible Equity Shareholders are also requested to ensure that their demat account, details of which have been provided to our Company or the Registrar account, is active to facilitate the aforementioned transfer. In the event that the Eligible Equity Shareholders are not able to provide the relevant details to our Company or the Registrar by the end of the two clear Working Days prior to the Issue Closing Date, Right Entitlements credited to the Demat Suspense Account shall lapse and extinguish in due course and such Eligible Equity Shareholders shall not have any claim against our Company and our Company shall not be liable to any such Eligible Equity Shareholders in any form or manner.

COMPLETION OF DISPATCH OF ISSUE MATERIAL

The dispatch of the Application Form, Letter of Offer dated January 20, 2026, and Right Entitlement Letter (Issue Material) has been completed on Thursday, January 29, 2026 for dispatch through email and for dispatch through Speed Post (Non-Email), as confirmed by the RTA. In case of Eligible Equity Shareholders who have provided their valid Email address to our Company, the Issue Material has been sent to their e-mail address and in case where Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material as applicable has been physically dispatched, on a reasonable effort basis, to the Indian addresses provided by them.

MAKING OF AN APPLICATION THROUGH THE ASBA PROCESS:

An Investor wishing to participate in the Issue through the ASBA facility is required to have an ASBA enabled bank account with SCSBs prior to making the application. Investors desiring to make an application in the Issue through the ASBA process, may submit the Application Form in physical mode to the Designated Branches of the SCSB or online/electronic application through the Website of the SCSBs (if made available by such SCSB) for authorizing such SCSB to block such Application Money payable on the Application in their respective ASBA Accounts. Investors should ensure that they have correctly submitted the Application Form and have provided an authorization to the SCSB, via the electronic mode or blocking funds in the ASBA Account equivalent to the Application Money mentioned in the Application Form, as the case may be, at the time of submission of the Application. For the list of Banks which have been notified by the SEBI to act SCSBs for the ASBA process, please refer to <https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFp=yes&intmid=34>.

MAKING OF AN APPLICATION BY ELIGIBLE EQUITY SHAREHOLDERS, ON PLAIN PAPER UNDER ASBA PROCESS

An Eligible Equity Shareholder in India who is eligible to apply under the ASBA process may make an Application to subscribe to this Issue on plain paper in terms of Regulation 78 of SEBI ICDR Regulations in case of non-receipt of the Application Form as detailed above. In such cases of non-receipt of the Application Form through e-mail or physical delivery (where applicable) and the Eligible Equity Shareholder not being in a position to obtain it from any other source may make an Application to subscribe to this Issue on plain paper with the same details as per the Application Form that is available on the website of the Company, Registrar or Stock Exchange. An Eligible Equity Shareholder shall submit the plain paper Application to the Designated Branch of the SCSB for authorising such SCSB to block Application Money in the said bank account maintained with the same SCSB. Applications on plain paper will not be accepted from any Eligible Equity Shareholder who has not provided an Indian address.

Please note that in terms of Regulation 78 of SEBI ICDR Regulations, the Eligible Equity Shareholders who are making the Application on plain paper shall not be entitled to renounce their Rights Entitlements and should not utilise the Application Form for any purpose, including renunciation even if it is received subsequently.

The Application on plain paper, duly signed by the Eligible Equity Shareholders including the joint holders, in the same order and as per the specimen recorder with his/her bank, must reach the office of the Designated branch of the SCSB before the Issue Closing Date and should contain the following particulars: 1. Name of our Company, being Dr Lalchandani Labs Limited 2. Name and address of the Eligible Equity Shareholder, including joint holders (in the same order as per the specimen recorded with our Company or the Depository) 3. Folio Number (in case of Eligible Equity Shareholders who hold Equity Shares in physical form as on the Record Date) DP and Client ID; 4. Except for Applications on behalf of the Central or State Government, the residents of Sikkim and the Officials appointed by the Courts, PAN of the Eligible Equity Shareholders and for each Eligible Equity Shareholder in case of joint names, irrespective of the total value of the Equity Shares applied for pursuant to this Issue. 5. Number of Equity Shares held as on Record Date; 6. Allotment option - only dematerialised form. 7. Number of Right Equity Shares entitled to 8. Total number of Right Equity Shares applied for 9. Number of additional Right Equity Shares applied for, if any (applicable only if entire Right Entitlements have been applied for); 10. Total number of Right Equity Shares applied for; 11. Total amount paid at the rate Rs. 10/- per Right Equity Share; 12. Details of the ASBA Account such as the SCSB account number, name, address and branch of the relevant SCSB; 13. In case of non-resident Eligible Equity Shareholders making an application with an Indian address, details of the NRE/FCNR/NRO account, such as the account number, name, address and the branch of the SCSB with which the account is maintained; 14. Authorisation to the Designated Branch of the SCSB to block an amount equivalent to the Application Money in the ASBA Account; 15. Signature of the Eligible Equity Shareholder (in case of joint holders, to appear in the same sequence and order as they appear in the records of the SCSB); and 16. All such Eligible Equity Shareholders shall be deemed to have made the representations, warranties and agreements set forth in Restrictions on Purchases and Resales - Eligible Investors' on Page 90 of Letter of Offer, and shall include the following:

I/We understand that neither the Rights Entitlements nor the Rights Equity Shares have been, or will be, registered under the U. S. Securities Act of 1933, as amended (the "U.S. Securities Act"). or any United States securities laws, and may not be offered, sold, resold, or otherwise transferred within the United States (including its territories and possessions thereof, any State of the United States and the District of Columbia) (the "United States"), except pursuant to an exemption from or in a transaction not subject to, the registration requirements of the U. S. Securities Act and in compliance with any applicable securities laws of any State of the United States in "offshore transactions" in reliance on Regulation S under the U.S. Securities Act ("Regulation S") to existing shareholders and located in jurisdictions where such offer and sale of the Right Equity Shares is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions. I/We understands that the issue is not and under no circumstances is to be construed as an offering of any Rights Equity Shares or Rights Entitlements for sale in the United States, or as a solicitation therein of an offer to buy any of said Rights Equity Shares or Rights Entitlements in the United States. I/we confirm that I/We (a) am/are not in the United States and am/are eligible to subscribe the Rights Equity Shares under applicable securities laws, (b) am/are complying with laws of jurisdictions applicable to such person in connection with the Issue, and (c) understand that neither the Company, nor the Registrar to the Issue, nor any other person acting on behalf of the Company will accept subscriptions from any person, or the agent of any person, who appears to be, or who the Company, the Registrar to the Issue or, any other person acting or acting on behalf of the Company have reason to believe is in the United States or is outside of India and ineligible to participate in this Issue under the securities laws of their jurisdiction. I/We will not offer, sell or otherwise transfer any of the Rights Equity Shares which may be acquired by us in any jurisdiction or under any circumstances in which such offer or sale is not authorised or to any person to whom it is unlawful to make such offer, sale or invitation.

I/We satisfy, and each account for which I/we are acting satisfies (a) all suitability standards for investors in investments of the type subscribed for herein, imposed by the jurisdiction of my/our residence, and (b) is eligible to subscribe and is subscribing for the Rights Equity Shares and Rights Entitlements in compliance with applicable securities and other laws of our jurisdiction of residence.

I/We acknowledge that the Company, its affiliates and other will rely upon the truth and accuracy of the foregoing representation and agreements."

In cases where Multiple Application Forms are submitted for Applications pertaining to Rights Entitlements

credited to the same demat account, including cases where an Investor submits Application Forms along with a plain paper Application, such Application shall be liable to be rejected.

Investors are requested to strictly adhere to these instructions. Failure to do so could result in an Application being rejected, with our Company and the Registrar and not having any liability to the Investor. The plain paper Application format will be available on the website of the Registrar (i.e. www.cameoindia.com) and the Stock Exchange, i.e. www.bseindia.com).

Our Company and the Registrar shall not be responsible if the Applications are not uploaded by the SCSB or funds are not blocked in the investors' ASBA Accounts on or before the Issue Closing Date.

If the shareholder makes an application using the Application Form as well as plain paper, both the applications shall be liable to be rejected at the option of the Issuer.

OVERSEAS SHAREHOLDERS: The distribution of Issue Materials and issue of Rights Entitlements, as well as Rights Equity Shares to persons in certain jurisdictions outside India, may be restricted by legal requirements prevailing in those jurisdictions. Persons into whose possession the Draft Letter of Offer, Letter of Offer, the Rights Entitlement Letter or Application Form may come or who receive Rights Entitlement and propose to renounce or apply for Rights Equity Shares in the issue are required to inform themselves about and observe such restrictions. For more details, See "Restrictions on Purchases and Resales" beginning on page 90 of the Letter of Offer. Our Company is undertaking this Issue on a rights basis to the Eligible Equity Shareholders and has dispatched the Application Form, the Rights Entitlement Letter, and other Issue material only to the email addresses of Eligible Equity Shareholders who have provided an Indian address to our Company. In case the Eligible Equity Shareholders have provided their valid e-mail address, the Issue material is sent only to their valid e-mail address and in case the Eligible Equity Shareholders have not provided their e-mail address, then the Issue Material is dispatched, on a reasonable effort basis, to the Indian addresses provided by them. Investors can also access the Letter of Offer and the Application Form from the websites of the Registrar to the Issue, our Company, and the BSE.

NO OFFER IN THE UNITED STATES: The Rights Entitlements and the Equity Shares have not been and will not be registered under the U. S. Securities Act, or any U. S. State Securities Laws and may not be offered, sold, resold or otherwise transferred within the United States, except in a transaction exempt from, or not subject to, the registration requirements of the U. S. Securities Act and applicable U. S. State Securities laws. Accordingly, the Equity Shares and the Rights Entitlements referred to in the Letter of Offer are being offered and sold only outside the United States in "offshore transactions" in reliance on Regulation S to existing shareholders located in jurisdictions where such offer and sale of the Equity Shares and/or rights entitlements is permitted under laws of such jurisdictions and in compliance with the applicable laws of such jurisdictions, the offering to which the Letter Of Offer relates is not and under no circumstances is to be construed as, an offering of any Equity Shares or Rights Entitlements for sale in the United States or as a solicitation therein of an offer to buy or transfer any of the said securities.

LAST DATE FOR APPLICATION: The last date for submission of the duly filled Application Form or a plain paper Application is Friday, February 20, 2026, i.e., Issue Closing Date. Our Board or any committee thereof may extend the said date for such period as, may determine from time to time, subject to the Issue Period not exceeding 30 days from the Issue Opening Date (inclusive of the Issue Opening Date).

If the Application Form is not submitted with an SCSB, uploaded with the Stock Exchanges and the Application Money is not blocked with the SCSB on or before the Issue Closing Date or such date as maybe extended by our Board or any committee thereof, the invitation to offer contained in the Letter of Offer shall be deemed to have been declined and our Board or any committee thereof shall be at liberty to dispose of the Equity Shares hereby offered, as set out in the section entitled "Terms of the Issue- Basis of Allotment" on page 84 or the Letter of Offer.

Please note that on the Issue Closing Date, Applications through ASBA process will be uploaded until 5:00 p.m. (Indian Standard Time) or such extended time as permitted by the Stock Exchange.

Please ensure that the Application Form and necessary details are filled in. In place of the Application number, investors can mention the reference number of the e-mail received from the Registrar informing about their Rights Entitlement or the last eight digits of the demat account. Alternatively, SCSBs may mention their internal reference number in place of the application number.

SPECIFIC INVESTORS: Pursuant to the provisions of Regulation 77B(1)(b) and 77B(4), Regulation 84(1)(i)/(ii), and Regulation 90(2)(d) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and in accordance with the disclosure regarding our Company's intention for allotment of the under-subscribed portion of the issue to Specific Investors under the title "Allotment of Under-Subscribed Portion of the Rights Issue" on page 17 of the Letter of Offer dated January 20, 2026, we provide the details of the Specific Investors in the Rights Issue of our Company as follows:

Sr. No.	Name of Specific Investor
1	Arjan Lal Chandani
2	Mohit Lal Chandani
3	Anchal Gupta
4	Harshpaul Singh Takkar
5	Rakesh Kumar Gambhir
6	Anuraag Gambhir
7	Rohit Tuli
8	Manav Kapoor
9	Saurabh Sehgal
10	Swapnil Khandelwal
11	Chaitanya Jain

Please note that the allotment to the above-specified Specific Investors shall be carried out in the manner specified under Regulation 90(2)(d) of the SEBI (ICDR) Regulations, 2018.

LISTING: The existing Equity Shares of our Company are listed on BSE Limited ("BSE"). Our Company has received "in-principle" approval from BSE for listing the Rights Equity Shares through its letter dated January 16, 2026. Our Company has made the necessary application to the Stock Exchange to obtain trading approval for Rights Entitlement as required under SEBI ICDR Master Circular.

DISCLAIMER CLAUSE OF BSE: It is to be distinctly understood that the permission given by BSE Limited should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE Limited, nor does it certify the correctness or completeness of any of the contents of the letter of offer. The Investors are advised to refer to the Letter of Offer for the full text of the disclaimer clause of BSE Limited under the heading "Other Regulatory and Statutory Disc

